Medtronic Elevates 2027 Forecasts Amid Rising Heart Device Demand

Medtronic has revised its fiscal 2027 revenue projections upward, citing robust demand for its advanced heart devices. The company now forecasts organic revenue growth between 7.25% and 7.75%, an increase from its previous estimate of 6.75% to 7.25%. This optimistic outlook reflects significant growth in the cardiovascular segment, where quarterly sales surged by 19.5% to $3.93 billion, largely due to an 88% increase in its pulsed field ablation portfolio.

Strategic Investments in Heart-Related Technologies

In a move to strengthen its foothold in cardiovascular technologies, Medtronic announced an $80 million investment in heart-valve repair device maker Pi-Cardia, with an option to acquire the company for $210 million. Additionally, Medtronic has committed $700 million to Cornerstone Robotics, securing distribution rights for a robotic surgical device in select international markets. Medtronic CEO Geoff Martha highlighted the synergy between Cornerstone's Sentire device and Medtronic's Hugo platform, particularly in emerging markets where robotic surgery penetration remains below 1%.

Financial Performance and Future Outlook

Medtronic's financial performance has exceeded expectations, with an adjusted quarterly profit of $1.45 per share on $9.76 billion in revenue, surpassing the anticipated $1.39 per share on $9.55 billion in sales. The company has also adjusted the lower end of its fiscal 2027 adjusted per-share profit forecast to $5.94 from $5.90, maintaining the upper end at $6. Medtronic's CFO Thierry Pieton noted that tariff refunds received nearly offset duties paid during the quarter, though future refunds have not been factored into the company's outlook.

CEO Geoff Martha expressed confidence in the company's growth trajectory, emphasizing the diverse performance across Medtronic's business units and the increasing impact of new growth platforms. He stated, "The steady cadence of mergers and acquisitions is focused on high-growth segments with large patient pools, ensuring sustainable expansion."

As Medtronic continues to capitalize on technological advancements in medical devices, its strategic investments and enhanced forecasts underscore its commitment to leading in the cardiovascular sector.